Skip to main content
. 2025 May 17;32:101878. doi: 10.1016/j.mtbio.2025.101878

Scheme 1.

Scheme 1

pH-responsive PEGylation strategy for the delivery of mPEG-CDM-modified sEVs, where the PEG coating stabilizes the vesicles under physiological conditions (pH ∼7.4), prolonging their circulation time, and is cleaved in acidic environments to promote their passive accumulation at disease sites in both glioma and ischemic stroke.